Website stats for Alnylam - alnylam.com
Alnylam Is the Leading RNAi Therapeutics Company Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an entirely new class of medicines. In , our first medicine, ONPATTRO (patisiran), became the world’s first approved RNAi therapeutic. We are advancing a robust pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medic...
alnylam.com was registered 2 decades 2 years ago. It has a alexa rank of #646,491 in the world. It is a domain having .com extension. It is estimated worth of $ 1,920.00 and have a daily income of around $ 8.00. As no active threats were reported recently, alnylam.com is SAFE to browse.
Traffic Report
| Daily Unique Visitors: | 1,356 |
| Daily Pageviews: | 2,712 |
Estimated Valuation
| Income Per Day: | $ 8.00 |
| Estimated Worth: | $ 1,920.00 |
Search Engine Indexes
| Google Indexed Pages: | Not Applicable |
| Yahoo Indexed Pages: | Not Applicable |
| Bing Indexed Pages: | Not Applicable |
Search Engine Backlinks
| Google Backlinks: | Not Applicable |
| Bing Backlinks: | Not Applicable |
| Alexa BackLinks: | Not Applicable |
Safety Information
| Google Safe Browsing: | No Risk Issues |
| Siteadvisor Rating: | Not Applicable |
| WOT Trustworthiness: |
 Very Poor
|
| WOT Privacy: |
Very Poor
|
| WOT Child Safety: |
Very Poor
|
Website Ranks & Scores
| Alexa Rank: | 646,491 |
| PageSpeed Score: | 40 ON 100 |
| Domain Authority: |
56 ON 100 
|
| Bounce Rate: | Not Applicable |
| Time On Site: | Not Applicable |
Web Server Information
Hosted IP Address:
23.185.0.2
Hosted Country:
US
Location Latitude:
37.792Location Longitude:
-122.407Traffic Classification
| Total Traffic: | No Data |
| Direct Traffic: | 40.33% |
| Referral Traffic: | 2.17% |
| Search Traffic: | 55.92% |
| Social Traffic: | 1.53% |
| Mail Traffic: | 0.05% |
| Display Traffic: | 0% |
Search Engine Results For alnylam.com
Alnylam® Pharmaceuticals
Alnylam Is the Leading RNAi Therapeutics Company. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an entirely new class of...
Investor Relations | Alnylam Pharmaceuticals, Inc.
The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for shareholders, potential investors, and financial analysts.
Alnylam Assist® Patient Support
Watch the video above to learn about Alnylam Assist®, a personalized support program that provides patients and healthcare professionals with the information and resources they...
Dec 03, 2020 Press Release for Alnylam - investors.alnylam.com
Renal function, frequency and mode of dialysis, frequency of renal stone events, and measures of systemic oxalosis will also be evaluated in the extension period of the study....
OXLUMOTM (lumasiran) - alnylam.com
- https://www.alnylam.com/wp-content/uploads/pdfs/OXLUMO-Product-Fact-Sheet.pdf
OXLUMOTM (lumasiran) Product Fact Sheet • OXLUMOTM (lumasiran) subcutaneous injection is approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary...
Alnylam® Newsroom
You are now leaving Alnylam.com. The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our...
Alnylam Pharmaceuticals - Wikipedia
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically...
Alnylam® Pharmaceuticals—The Leading RNAi Therapeutics ...
Alnylam is leading the translation of RNA interference (RNAi) into a innovative, entirely new class of medicines which we believe have the potential to transform the lives of...
OXLUMOTM (lumasiran) - alnylam.com
- https://www.alnylam.com/wp-content/uploads/pdfs/OXLUMO-Product-Fact-Sheet.pdf
OXLUMOTM (lumasiran) Product Fact Sheet • OXLUMOTM (lumasiran) subcutaneous injection is approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary...
Dec 03, 2020 Press Release for Alnylam - investors.alnylam.com
Renal function, frequency and mode of dialysis, frequency of renal stone events, and measures of systemic oxalosis will also be evaluated in the extension period of the study....
Alnylam® Science of RNA Interference (RNAi) | Canada
Our science and drug development platform is based on RNA interference (RNAi) - a breakthrough in understanding how genes are regulated in cells and the recipient of …
Alnylam® Pharmaceuticals | Leader nei farmaci basati sull ...
Alnylam è in prima linea nell'utilizzo dell’interferenza dell’RNA (RNAi) per creare una nuova classe di farmaci che riteniamo abbiano il potenziale per cambiare …
Alnylam - Principal Empresa de Terapia de RNAi | Brasil
A Alnylam está liderando a tradução da Interferência de RNA (RNAi) em uma classe de medicamentos totalmente inovadora, que acreditamos ter o potencial de transformar a vida de...
Alnylam®Japan(アルナイラム)はRNAiのリーディングカンパニー …
私たちAlnylam(アルナイラム）はRNAi治療薬と呼ばれる新たな作用メカニズムの新薬を開発しています。RNAi治療薬には、希少疾患を持つ人々の暮らしを変える可能性があると私たちは考えています。
Job Search - alnylam.taleo.net
Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.
Home | ONPATTRO® (patisiran)
Important Safety Information Infusion-Related Reactions. Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO ® (patisiran).In a controlled...
Legal Notice | Alnylam Policies
Nov 13, 2019 · These Terms and Conditions apply only to www.alnylam.com This web site may contain links to non-Alnylam web sites. These links are provided to you as a...
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study ...
1 day ago · Renal function, frequency and mode of dialysis, frequency of renal stone events, and measures of systemic oxalosis will also be evaluated in the extension period of...
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
| H1 Headings: | Not Applicable | H2 Headings: | 18 |
| H3 Headings: | 27 | H4 Headings: | 7 |
| H5 Headings: | 1 | H6 Headings: | Not Applicable |
| Total IFRAMEs: | 1 | Total Images: | 27 |
| Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
Two Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| Alnylam Pharmaceuticals | 53 | 2.431 % | No |
| are now | 27 | 1.239 % | No |
| You are | 27 | 1.239 % | No |
| 24 | 1.101 % | No | |
| to Site | 22 | 1.009 % | No |
| now leaving | 22 | 1.009 % | No |
| leaving Alnylamcom | 22 | 1.009 % | No |
| Proceed to | 22 | 1.009 % | No |
| Site × | 20 | 0.917 % | No |
| × You | 18 | 0.826 % | No |
| for the | 18 | 0.826 % | No |
| to all | 17 | 0.78 % | No |
| outside sites | 17 | 0.78 % | No |
| all outside | 17 | 0.78 % | No |
| sites are | 17 | 0.78 % | No |
| reference for | 17 | 0.78 % | No |
| for our | 17 | 0.78 % | No |
| Links to | 17 | 0.78 % | No |
| a reference | 17 | 0.78 % | No |
| provided as | 17 | 0.78 % | No |
Four Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| You are now leaving | 22 | 1.009 % | No |
| are now leaving Alnylamcom | 22 | 1.009 % | No |
| Proceed to Site × | 20 | 0.917 % | No |
| to Site × You | 18 | 0.826 % | No |
| × You are now | 18 | 0.826 % | No |
| Site × You are | 18 | 0.826 % | No |
| are provided as a | 17 | 0.78 % | No |
| now leaving Alnylamcom The | 17 | 0.78 % | No |
| sites are provided as | 17 | 0.78 % | No |
| outside sites are provided | 17 | 0.78 % | No |
| all outside sites are | 17 | 0.78 % | No |
| as a reference for | 17 | 0.78 % | No |
| a reference for our | 17 | 0.78 % | No |
| visitors Alnylam Pharmaceuticals does | 17 | 0.78 % | No |
| Alnylam Pharmaceuticals does not | 17 | 0.78 % | No |
| our visitors Alnylam Pharmaceuticals | 17 | 0.78 % | No |
| for our visitors Alnylam | 17 | 0.78 % | No |
| reference for our visitors | 17 | 0.78 % | No |
| to all outside sites | 17 | 0.78 % | No |
| Links to all outside | 17 | 0.78 % | No |
Websites Hosted on Same IP (i.e. 23.185.0.2)
Numerix
Numerix is a leading provider of innovative capital markets technology solutions and real-time intelligence capabilities for trading and risk management.
1,236,473 
$ 960.00
Sydney Living Museums
Sydney Living Museums is a group of 12 museums, houses and gardens that will take you on a remarkable journey through time and place to experience a whole other life.
3,818,662 $ 240.00
TNS - Payment, Telecoms & Financial Data Solutions
TNS is a leading global provider of data communications and interoperability solutions for the payments, telecom and financial markets industries
618,489 $ 2,160.00
HTTP Header Analysis
Status-Code: 200
Status: 200 OK
Connection: keep-alive
Cache-Control: public, max-age=360
Content-Encoding: gzip
Content-Type: text/html; charset=UTF-8
Link:
Server: nginx
Strict-Transport-Security: max-age=300
X-Pantheon-Styx-Hostname: styx-fe2-a-5d5d6985d5-bcmnb
X-Styx-Req-Id: 0b3a9056-fcd2-11e9-b05e-0e0ec9502d09
Date: Fri, 01 Nov 2019 18:04:28 GMT
X-Served-By: cache-mdw17336-MDW, cache-hhn4039-HHN
X-Cache: MISS, MISS
X-Cache-Hits: 0, 0
X-Timer: S1572631467.267166,VS0,VE942
Vary: Accept-Encoding, Cookie, Cookie
Age: 0
Accept-Ranges: bytes
Via: 1.1 varnish
transfer-encoding: chunked
Domain Information
| Domain Registrar: |
Network Solutions, LLC
|
|---|---|
| Registration Date: | 2002-06-26 2 decades 2 years 4 months ago |
| Last Modified: | 2019-10-17 5 years 1 month 5 days ago |
Domain Nameserver Information
| Host | IP Address | Country | |
|---|---|---|---|
| dns1.easydns.com | |
64.68.196.10 |  Canada |
| dns2.easydns.net | |
64.68.193.10 | Canada |
DNS Record Analysis
| Host | Type | TTL | Extra |
|---|---|---|---|
| alnylam.com | A | 1177 |
IP: 23.185.0.2 |
| alnylam.com | NS | 1200 |
Target: dns1.easydns.com |
| alnylam.com | NS | 1200 |
Target: dns3.easydns.org |
| alnylam.com | NS | 1200 |
Target: dns2.easydns.net |
| alnylam.com | SOA | 1200 |
MNAME: dns1.easydns.com RNAME: zone.easydns.com Serial: 1561854043 Refresh: 21600 Retry: 7200 Expire: 1209600 |
| alnylam.com | MX | 600 |
Priority: 10 Target: us-smtp-inbound-2.mimecast.com |
| alnylam.com | MX | 600 |
Priority: 10 Target: us-smtp-inbound-1.mimecast.com |
| alnylam.com | TXT | 1200 |
TXT: kVSaLVMqaQRcv4TRSIBJfpUkOviIR1bBBkyRZ1Dh ea4LFe097nAeL30idhcRTB3qfsHtlO1XQIMBfbyr PlE8Bw== |
| alnylam.com | TXT | 1200 |
TXT: v=spf1 include:spf.protection.outlook.com include:spf.zixsmbhosted.com ip4:207.211.31.0/25 ip4:209.59.2.0/25 a:apollotrial.com mx include:mailgun.org ~all |
| alnylam.com | TXT | 1200 |
TXT: docusign=9ddeb178-1b3b-46ef-a4d4-b7be43b c7c17 |
| alnylam.com | TXT | 1200 |
TXT: docusign=08769ca5-0790-4bcd-9a6d-235d4e0 b79ac |
| alnylam.com | TXT | 1200 |
TXT: amazonses:MKpyvQ9U/vjvCqdMQk6iduchgeLir2 l9/fCHOz3b+Fo= |
| alnylam.com | TXT | 1200 |
TXT: amazonses:a2C46xffURhDKZOvhSlUR54C4fzT6d snvw2WJ2PP4es= |
| alnylam.com | TXT | 1200 |
TXT: 51gbr0kash88daipucp9jjopje |
Top Organic Keyword
| 1. | alnylam |
| 2. | alnylam pharmaceuticals |
| 3. | alnylam pharmaceuticals inc |
| 4. | alnylam cfo |
| 5. | bank of america merrill lynch healthcare conference webcast |
Top Paid Keyword
| Not Applicable |
Top Referral Site
| 1. | fiercebiotech.com |
| 2. | biopharmguy.com |
| 3. | hollandbio.nl |
| 4. | finance.yahoo.com |
Top Destination Site
| 1. | alnylam.taleo.net |
Full WHOIS Lookup
Registry Domain ID:
87888233_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.networksolutions.com
Registrar URL:
http://networksolutions.com
Updated Date:
2019-10-17T15:51:56Z
Creation Date:
2002-06-26T13:42:59Z
Registry Expiry Date:
2020-06-26T13:48:15Z
Registrar: Network Solutions,
LLC
Registrar IANA ID: 2
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
+1.8003337680
Domain Status: clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Name Server:
DNS1.EASYDNS.COM
Name Server: DNS2.EASYDNS.NET
DNSSEC:
unsigned
URL of the ICANN Whois Inaccuracy Complaint Form:
https://www.icann.org/wicf/
>>> Last update of whois database:
2019-11-01T18:04:38Z
Similarly Ranked Websites
Trouver vos études dans l’enseignement supérieur en Belgique...
Trouver vos études dans l’enseignement supérieur en Belgique francophone, les bourses d’études, les aspects pratiques de votre séjour. WB Campus vous guide.
646,498 $ 1,920.00
Square Roots
Square Roots is an indoor urban farming company connecting people in cities to local, real food.
646,503 $ 1,920.00
Continuous Integration and Deployment for iOS | buddybuild
A continuous integration, continuous deployment, and user feedback platform for iOS development teams. Get up and running today.
646,503 $ 1,920.00